• OPEN AN ACCOUNT
Indian Indices
Nifty
24,750.70 -82.90
(-0.33%)
Sensex
81,451.01 -182.01
( -0.22%)
Bank Nifty
55,749.70 203.65
( 0.37%)
Nifty IT
37,321.75 -432.40
( -1.15%)
Global Indices
Nasdaq
42,280.67 43.94
(0.10%)
Dow Jones
5,931.28 -1.89
(-0.03%)
Hang Seng
38,097.61 -335.37
(-0.87%)
Nikkei 225
8,772.38 55.93
(0.64%)
Forex
USD-INR
85.50 0.07
(0.09%)
EUR-INR
97.01 0.42
(0.44%)
GBP-INR
115.18 0.03
(0.03%)
JPY-INR
0.59 0.00
(0.53%)

EQUITY - MARKET SCREENER

Ridhi Synthetics Ltd
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
504365
INE07LK01010
414.8252912
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0.46
0.49
EPS(TTM)
Face Value()
Div & Yield %
8.91
10
0
 

aditya birla sun life crisil liquid overnight etf
Lupin rises after launching Talvaptan tablets in US market
May 13,2025
The tablets are the generic version of Jynarque, developed by Otsuka Pharmaceutical Company, and are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

The product has an estimated annual market size of $1,467 million in the U.S. for the fiscal year ended 31 December 2024.

Vinita Gupta, CEO of Lupin, said, “We are pleased to announce the launch of Tolvaptan Tablets in the U.S. to provide ADPKD patients with increased access to high-quality treatment options.”

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company’s consolidated net profit jumped 39.5% to Rs 855.16 crore in Q3 FY25 as compared with Rs 613.12 crore in Q4 FY24. Net sales increased 10.6% YoY to Rs 5618.56 crore during the quarter ended 31st March 2025.